Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor

Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated success in the treatment of hematological malignancies; however, its efficacy and applications in solid tumors remain limited. Immunosuppressive factors, particularly inhibitory checkpoint molecules, restrict CAR T cell activity i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jingjing, Dong, Jiebin, Deng, Changwen, Zhang, Qianjing, Sun, Shicheng, Li, Honggang, Bai, Yun, Deng, Hongkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557556/
https://www.ncbi.nlm.nih.gov/pubmed/37808405
http://dx.doi.org/10.1080/2162402X.2023.2265703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557556/
https://www.ncbi.nlm.nih.gov/pubmed/37808405
http://dx.doi.org/10.1080/2162402X.2023.2265703

Ejemplares similares